Amgen Reports Positive Phase 3 Results for Dazodalibep in Sjögren's Disease
Product·2 articles across 2 outlets·◆ Primary source
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Amgen announced positive topline results from a Phase 3 study of its drug candidate, dazodalibep, for treating moderate-to-severe systemic Sjögren's disease. The drug, acquired through Amgen's buyout of Horizon Therapeutics, has shown promising efficacy in this patient population.
The results mark a significant milestone for Amgen as it seeks to expand its portfolio in autoimmune diseases. Dazodalibep's success in this trial could enhance treatment options for patients suffering from this chronic condition.
Amgen
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE”
SEC Filing — AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE“<figure><div><img”
biopharma dive — Amgen reports a Phase 3 win with Sjögren’s drug candidate